Angion Biomedica Corp. – NASDAQ:ANGN

Financial Health
0
1
2
3
4
5
6
7
8
9

Angion Biomedica Corp. stock price monthly change

+26.67%
month

Angion Biomedica Corp. stock price quarterly change

+43.92%
quarter

Angion Biomedica Corp. stock price yearly change

-28.03%
year

Angion Biomedica Corp. key metrics

Market Cap
30.11M
Enterprise value
N/A
P/E
-0.37
EV/Sales
-13.93
EV/EBITDA
0.86
Price/Sales
6.39
Price/Book
0.33
PEG ratio
-0.01
EPS
-4.24
Revenue
N/A
EBITDA
-23.75M
Income
-34.19M
Revenue Q/Q
N/A
Revenue Y/Y
-100%
Profit margin
-1686.53%
Oper. margin
-1463.62%
Gross margin
0%
EBIT margin
-1463.62%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Angion Biomedica Corp. stock price history

Angion Biomedica Corp. stock forecast

Angion Biomedica Corp. financial statements

Angion Biomedica Corp. (NASDAQ:ANGN): Profit margin
Dec 2022 0 -11.51M
Mar 2023 0 -4.46M
Jun 2023 0 -7.55M
Sep 2023 0 -10.65M
Angion Biomedica Corp. (NASDAQ:ANGN): Earnings per share (EPS)
2023-08-21 0.57 -2.43763
Angion Biomedica Corp. (NASDAQ:ANGN): Debt to assets
Dec 2022 52790000 9.01M 17.08%
Mar 2023 41767000 2.10M 5.03%
Jun 2023 37619000 14.06M 37.38%
Sep 2023 30987000 17.70M 57.12%
Angion Biomedica Corp. (NASDAQ:ANGN): Cash Flow
Jun 2022 -9.90M 0 -14K
Sep 2022 -8.40M 0 -17K
Dec 2022 -4.42M 0 -15K
Mar 2023 -8.07M -10M -3.26M

Angion Biomedica Corp. alternative data

Angion Biomedica Corp. (NASDAQ:ANGN): Employee count
Aug 2023 3
Sep 2023 3
Oct 2023 3
Nov 2023 3
Dec 2023 3
Jan 2024 3
Feb 2024 3
Mar 2024 3
Apr 2024 3
May 2024 3
Jun 2024 3
Jul 2024 3

Angion Biomedica Corp. other data

4.18% -12.13%
of ANGN is owned by hedge funds
1.25M -3.65M
shares is hold by hedge funds

Angion Biomedica Corp. (NASDAQ:ANGN): Insider trades (number of shares)
Period Buy Sel
Dec 2023 1213000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
CHUDNOVSKY YEKATERINA director, 10 percent owner:
Common Stock 1,213,000 $5.81 $7,047,530
Purchase
VENKATESAN JAY director, officer:
Common Stock 11,313 $1.25 $14,107
Purchase
VENKATESAN JAY director, officer: President an..
Common Stock 32,200 $1.24 $39,928
Purchase
NISSENSON ALLEN director
Common Stock 2,037 $1.18 $2,404
Purchase
VENKATESAN JAY director, officer: President an..
Common Stock 50,000 $1.23 $61,500
Purchase
NISSENSON ALLEN director
Common Stock 7,346 $1.16 $8,521
Purchase
VENKATESAN JAY director, officer: President an..
Common Stock 210,337 $2.66 $559,917
Purchase
VENKATESAN JAY director, officer: President an..
Common Stock 66,907 $2.55 $170,546
Purchase
VENKATESAN JAY director, officer: President an..
Common Stock 3,527 $2.55 $8,976
Sale
NEYLAN JOHN F. officer: Senior Vice President ..
Common Stock 358 $2.62 $938
Insider Compensation
Ms. Jennifer J. Rhodes J.D. (1970) Senior Vice President, Gen. Counsel, Chief Compliance Officer & Corporation Sec. $500,000
Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D. (1972) Pres, Chief Executive Officer & Director
$390,000
Mr. Gregory S. Curhan (1962) Interim Chief Financial Officer
$359,010
Wednesday, 18 January 2023
Zacks Investment Research
Wednesday, 16 November 2022
Zacks Investment Research
Tuesday, 25 October 2022
Zacks Investment Research
Thursday, 30 June 2022
Benzinga
Wednesday, 1 June 2022
PennyStocks
Wednesday, 11 May 2022
Zacks Investment Research
Monday, 13 December 2021
Zacks Investment Research
Monday, 18 October 2021
GlobeNewsWire
Wednesday, 8 September 2021
GlobeNewsWire
Thursday, 2 September 2021
GlobeNewsWire
  • When is Angion Biomedica Corp.'s next earnings date?

    Unfortunately, Angion Biomedica Corp.'s (ANGN) next earnings date is currently unknown.

  • Does Angion Biomedica Corp. pay dividends?

    No, Angion Biomedica Corp. does not pay dividends.

  • How much money does Angion Biomedica Corp. make?

    Angion Biomedica Corp. has a market capitalization of 30.11M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 91.87% to 2.3M US dollars. Angion Biomedica Corp. made a loss 55.7M US dollars in net income (profit) last year or -$2.44 on an earnings per share basis.

  • What is Angion Biomedica Corp.'s stock symbol?

    Angion Biomedica Corp. is traded on the NASDAQ under the ticker symbol "ANGN".

  • What is Angion Biomedica Corp.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Angion Biomedica Corp.?

    Shares of Angion Biomedica Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Angion Biomedica Corp.'s key executives?

    Angion Biomedica Corp.'s management team includes the following people:

    • Ms. Jennifer J. Rhodes J.D. Senior Vice President, Gen. Counsel, Chief Compliance Officer & Corporation Sec.(age: 55, pay: $500,000)
    • Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D. Pres, Chief Executive Officer & Director(age: 53, pay: $390,000)
    • Mr. Gregory S. Curhan Interim Chief Financial Officer(age: 63, pay: $359,010)
  • How many employees does Angion Biomedica Corp. have?

    As Jul 2024, Angion Biomedica Corp. employs 3 workers.

  • When Angion Biomedica Corp. went public?

    Angion Biomedica Corp. is publicly traded company for more then 4 years since IPO on 5 Feb 2021.

  • What is Angion Biomedica Corp.'s official website?

    The official website for Angion Biomedica Corp. is angion.com.

  • Where are Angion Biomedica Corp.'s headquarters?

    Angion Biomedica Corp. is headquartered at 51 Charles Lindbergh Boulevard, Uniondale, NY.

  • How can i contact Angion Biomedica Corp.?

    Angion Biomedica Corp.'s mailing address is 51 Charles Lindbergh Boulevard, Uniondale, NY and company can be reached via phone at +41 56554899.

Angion Biomedica Corp. company profile:

Angion Biomedica Corp.

angion.com
Exchange:

NASDAQ

Full time employees:

3

Industry:

Biotechnology

Sector:

Healthcare

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.

51 Charles Lindbergh Boulevard
Uniondale, NY 11553

CIK: 0001601485
ISIN: US03476J1079
CUSIP: 03476J107